Predict your next investment

Private Equity
scvc.cn

See what CB Insights has to offer

Investments

36

Portfolio Exits

5

Funds

3

About South China Venture Capital

South China Venture Capital is a private equity investment fund management and venture capital investment firm.

South China Venture Capital Headquarter Location

Room 1802, Building A Aerospace Science And Technology Square, 3rd Haide Road, Nanshan District

Shenzhen, Guangdong, 518054,

China

+86 0755-82520688

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest South China Venture Capital News

Drug Farm Closes $56M Financing

Feb 9, 2021

Drug Farm , a Shangai, China- and Guilford, MA-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, completed financing totaling $56m USD. Backers included BioVeda China Fund (BVCF), WuXi AppTec’s corporate venture fund, South China Venture Capital (SCVC), Detong Capital, and Zhejiang United Investment Group (ZUIG). The company intends to use the funds to initiate human clinical trials with its lead drug DF-006, an orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases and to further advance its additional pipeline candidates for therapies in cancer and autoimmune diseases. Led by Dr. Tian Xu, founder and Chairman, and Dr. Henri Lichenstein, CEO and Board Member, Drug Farm is a biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Its IDInVivo platform combines technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. FinSMEs 09/02/2021

South China Venture Capital Investments

36 Investments

South China Venture Capital has made 36 investments. Their latest investment was in IC Real as part of their Series A - II on December 12, 2021.

CBI Logo

South China Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/1/2021

Series A - II

IC Real

No

1

7/29/2021

Unattributed VC - II

Angshite

Yes

1

6/1/2021

Series C

Inmagene Biopharmaceuticals

$100M

No

5

5/31/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/1/2021

7/29/2021

6/1/2021

5/31/2021

4/27/2021

Round

Series A - II

Unattributed VC - II

Series C

Series B

Series A

Company

IC Real

Angshite

Inmagene Biopharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$100M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

5

10

10

South China Venture Capital Portfolio Exits

5 Portfolio Exits

South China Venture Capital has 5 portfolio exits. Their latest portfolio exit was CARsgen Therapeutics on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/18/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

South China Venture Capital Fund History

3 Fund Histories

South China Venture Capital has 3 funds, including Zhongnan PreAngel Capital Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/5/2017

Zhongnan PreAngel Capital Fund III

Early-Stage Venture Capital

$7.69M

1

5/1/2012

South China Selected (Tianjin) Pharmaceutical Equity Investment Fund LP

Subscribe to see more

$99M

10

12/31/2010

South China Growth (Tianjin) Equity Investment Fund Management LP

Subscribe to see more

$99M

10

Closing Date

1/5/2017

5/1/2012

12/31/2010

Fund

Zhongnan PreAngel Capital Fund III

South China Selected (Tianjin) Pharmaceutical Equity Investment Fund LP

South China Growth (Tianjin) Equity Investment Fund Management LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Amount

$7.69M

$99M

$99M

Sources

1

10

10

South China Venture Capital Team

1 Team Member

South China Venture Capital has 1 team member, including current Managing Director, Qingfeng Zheng.

Name

Work History

Title

Status

Qingfeng Zheng

Managing Director

Current

Name

Qingfeng Zheng

Work History

Title

Managing Director

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.